Premium
ADENOSINE 5′‐DIPHOSPHATE ANTAGONISTS AND HUMAN PLATELETS: NO EVIDENCE THAT AGGREGATION AND INHIBITION OF STIMULATED ADENYLATE CYCLASE ARE MEDIATED BY DIFFERENT RECEPTORS
Author(s) -
CUSACK N.J.,
HOURANI S.M.O.
Publication year - 1982
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1982.tb09210.x
Subject(s) - adenylate kinase , cyclase , adenosine diphosphate , adenosine , receptor , adenine nucleotide , platelet , chemistry , antagonist , adenosine triphosphate , endocrinology , medicine , biochemistry , nucleotide , biology , platelet aggregation , gene
1 Adenosine 5′‐diphosphate (ADP) induces human platelet aggregation and noncompetitively inhibits stimulated human platelet adenylate cyclase; it has been suggested that these two effects are mediated by separate ADP receptors on the platelet surface. 2 Adenosine 5′‐triphosphate and seven adenine nucleotide analogues were tested as inhibitors of both effects of ADP on human platelets, and were found to be competitive. 3 pA 2 values were calculated for each antagonist for inhibition of both effects of ADP, and a good correlation (correlation coefficient 0.87; P < 0.01) was found between the pA 2 values for inhibition of ADP‐induced aggregation and the pA 2 values for inhibition of the effect of ADP on stimulated adenylate cyclase. 4 Such a correlation does not support the suggestion that ADP‐induced aggregation and the inhibition by ADP of stimulated adenylate cyclase are mediated by two separate receptors.